Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents and Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents – Last updated February 12, 2013. Section: HIV and the older patient, page I31. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed March 03, 2014..
   Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Winston JA, Dejesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22:2155–2163.
   PubMed Web of Science ®Google Scholar
• Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10:329–336.
   PubMed Web of Science ®Google Scholar
• Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS. 2009;23:2143–2149.
   PubMed Web of Science ®Google Scholar
• O'Donnell EP, Scarsi KK, Darin KM, Gerzenshtein L, Postelnick MJ, Palella FJ Jr. Low incidence of renal impairment observed in tenofovir-treated patients. J Antimicrob Chemother. 2011;66:1120–1126.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 2007;21:1119–1127.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004;18:1074–1076.
   PubMed Web of Science ®Google Scholar
• Deti EK, Thiebaut R, Bonnet F, et al. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med. 2010;11:308–317.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–1126.
   PubMed Web of Science ®Google Scholar
• Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53:1130–1139.
   PubMed Web of Science ®Google Scholar
• Blanco JR, Caro-Murillo AM, Castano MA, et al. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. HIV Clin Trials. 2013;14:204–215.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585.
   PubMed Web of Science ®Google Scholar
• Winston J, Deray G, Hawkins T, Szczech L, Wyatt C, Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis. 2008;47:1449–1457.
   PubMed Web of Science ®Google Scholar
• Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12:1165–1173.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Ganesan A, Teneza-Mora N, et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS. 2010;24:353–360.
   PubMed Web of Science ®Google Scholar
• Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009;25:387–394.
   PubMed Web of Science ®Google Scholar
• Young J, Schafer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS. 2012;26:567–575.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;23:1971–1975.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102–108.
   PubMed Web of Science ®Google Scholar
• Young B, Buchacz K, Moorman A, Wood KC, Brooks JT. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study. AIDS Patient Care STDS. 2009;23:589–592.
   PubMed Web of Science ®Google Scholar
• Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278–283.
   PubMed Web of Science ®Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT Study. J Acquir Immune Defic Syndr. 2010;55:49–57.
   PubMed Web of Science ®Google Scholar
• Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283–290.
   PubMed Web of Science ®Google Scholar
• Lubomirov R, Colombo S, di IJ, et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis. 2011;203:246–257.
   PubMed Web of Science ®Google Scholar
• Nishijima T, Gatanaga H, Komatsu H, et al. Renal function declines more in tenofovir-than abacavir-based antiretroviral therapy in low-body weight treatment-naive patients with HIV infection. PLoS One. 2012;7:e29977.
   PubMed Web of Science ®Google Scholar